Purpose: Efficient antigen delivery remains a major challenge for dendritic cell (DC)-based immunotherapy of solid-organ malignancies. Soluble tumor lysates suffer from instability, poor DC internalization, and inefficient cross-presentation to cytotoxic T lymphocytes. PLGA nanoparticles may protect antigens, improve loading, prolong release, and enhance MHC-peptide presentation.
Hypothesis: If tumor-associated antigens (TAAs) from tumor lysates are encapsulated in biodegradable PLGA nanoparticles before delivery to dendritic cells, then antitumor CD8+ T-cell responses will be enhanced compared with delivery of the same antigens in soluble form.
Aims: Generate PLGA nanoparticles containing TAAs from head and neck squamous cell carcinoma (HNSCC) cell lines and fresh patient tumor lysates. - Characterize nanoparticle size, morphology, encapsulation efficiency, release kinetics, and protein integrity. - Load patient-derived dendritic cells with soluble vs nanoparticle-encapsulated tumor lysates. - Assess stimulation of autologous CD8+ T cells by measuring IFN-γ and IL-10 production. - Compare nanoparticle-mediated delivery with soluble lysate and blank nanoparticles.
Delivery system:
Component: Polymer; Details: Poly(lactic-co-glycolic acid) (PLGA), 50:50 lactide:glycolide
Component: Molecular weights; Details: 45 kDa or 80 kDa
Component: Stabilizer; Details: 0.5% polyvinyl alcohol (PVA)
Component: Nanoparticle type; Details: PLGA nanoparticles
Component: Payload; Details: Tumor lysates / tumor-associated antigens from HNSCC cell lines and fresh patient tumors
Component: Encapsulation method; Details: Water/oil/water (W₂/O/W₁) solvent evaporation; lyophilized lysate also used for direct O/W₁ encapsulation
Component: Targeting ligand; Details: None
Component: Size; Details: ~310 nm (soluble lysate NPs); ~392 nm (lyophilized lysate NPs)
Component: Key feature; Details: Encapsulation of complex, patient-derived tumor antigen mixtures for DC loading
Approach: In vitro only. No in vivo animal tumor models. - Cell lines: FaDu and FAT7 HNSCC lines for optimization. - Human samples: Five patients with stage III/IV HNSCC; fresh tumor tissue and peripheral blood. - DC generation: Monocyte-derived DCs from peripheral blood; matured with LPS. - T-cell stimulation: Autologous CD8+ T cells co-cultured with DCs loaded with soluble lysate, NP-encapsulated lysate, or blank NPs. - Controls: Blank NPs, no-antigen controls, unstimulated CD8+ T cells. - Doses: 0.5 mg NPs per 1 × 10⁶ DCs; soluble lysate used at fivefold excess antigen. - Readout: Cytokine production (IFN-γ, IL-10, IL-2, IL-4, IL-6, TNF-α).
Key methods: Nanoparticle characterization: Scanning electron microscopy (SEM), ImageJ sizing. - Protein encapsulation/release: Bicinchoninic acid (BCA) assay; cumulative release over 7 days. - Protein integrity/composition: SDS-PAGE with silver staining; Western blot for p53. - DC/T-cell co-culture: Cytometric bead array for cytokine profiling. - Statistics: Spearman’s rho, Mann–Whitney U, Kruskal–Wallis tests; p < 0.05 considered significant.
Key results: Encapsulation: Increased with lysate concentration; Pearson correlation 0.92 for 45-kDa PLGA and 0.95 for 80-kDa PLGA. Lyophilized lysate improved encapsulation and release. - Release: Biphasic release over 7 days; higher protein content led to greater cumulative release. Lyophilized-lysate NPs released significantly more protein than soluble-lysate NPs (p = 0.049). - Protein integrity: p53 was retained after encapsulation and release; SDS-PAGE showed a broad spectrum of tumor-associated proteins. - Immune response: In 4 of 5 patients, NP-mediated antigen delivery significantly increased IFN-γ (p = 0.0071) or decreased IL-10 (p = 0.0004) compared with soluble lysate. NP vs blank NPs: IFN-γ p = 0.028; IL-10 p = 0.049. - Other cytokines: No statistically significant differences in IL-2, IL-4, IL-6, or TNF-α. - Efficiency: NPs delivered fivefold less antigen than soluble lysate yet evoked stronger favorable cytokine responses.
Interpretation: The authors claim that PLGA nanoparticle-mediated delivery of whole-tumor lysates is more efficient than conventional soluble lysate in evoking favorable CD8+ T-cell-driven antitumor cytokine responses. This strategy is described as an enabling step toward clinically translatable, inexpensive, personalized polymer-based immunotherapy for solid-organ malignancies, with potential to overcome tumor tolerance and improve disease control.
Limitations: In vitro only: No in vivo tumor challenge, survival, or therapeutic efficacy. - Small patient cohort: n = 5; inter-patient variability. - No direct cytotoxicity assay: Only cytokine readouts; no CTL killing, tetramer, or functional cytotoxicity data. - No targeting ligand: Delivery relies on passive DC uptake. - No standardized dose: NP-to-DC ratio chosen empirically. - No long-term memory or persistence data. - No comparison with clinical-grade DC vaccines or other adjuvants. - No assessment of regulatory, manufacturing, or stability issues. - DOI/link not provided in the supplied file.
